New targeted therapies for thyroid cancer

Alessandro Antonelli, Poupak Fallahi, Silvia M. Ferrari, Ilaria Ruffilli, Francesca Santini, Michele Minuto, David Galleri, Paolo Miccoli

Research output: Contribution to journalArticle

Abstract

The increasing incidence of thyroid cancer is associated with a higher number of advanced disease characterized by the loss of cancer differentiation and metastatic spread. The knowledge of the molecular pathways involved in the pathogenesis of thyroid cancer has made possible the development of new therapeutic drugs able to blockade the oncogenic kinases (BRAF V600E, RET/PTC) or signaling kinases [vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptors (PDGFR)] involved in cellular growth and proliferation. Some clinical trials have been conducted showing the ability of targeted therapies (sorafenib, sunitinib, axitinib, imanitib, vandetanib, pazopanib, gefitinib) in stabilizing the course of the disease. Until now, however, no consensus guidelines have been established for patient selection and more data on toxicities and side effects are needed to be collected.

Original languageEnglish
Pages (from-to)626-631
Number of pages6
JournalCurrent Genomics
Volume12
Issue number8
DOIs
Publication statusPublished - Dec 2011

Fingerprint

Thyroid Neoplasms
Proto-Oncogene Proteins B-raf
Platelet-Derived Growth Factor Receptors
Vascular Endothelial Growth Factor Receptor
Factor IX
Patient Selection
Phosphotransferases
Cell Proliferation
Clinical Trials
Guidelines
Incidence
Therapeutics
Growth
Pharmaceutical Preparations
Neoplasms
gefitinib
pazopanib
sorafenib
sunitinib
N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine

Keywords

  • Anaplastic thyroid cancer
  • Aurora kinase inhibitors
  • BRAF
  • Peroxisome proliferator-activated receptor-γ
  • RET
  • Targeted molecular therapies
  • Tyrosine kinase inhibitors
  • VEGFR

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Antonelli, A., Fallahi, P., Ferrari, S. M., Ruffilli, I., Santini, F., Minuto, M., ... Miccoli, P. (2011). New targeted therapies for thyroid cancer. Current Genomics, 12(8), 626-631. https://doi.org/10.2174/138920211798120808

New targeted therapies for thyroid cancer. / Antonelli, Alessandro; Fallahi, Poupak; Ferrari, Silvia M.; Ruffilli, Ilaria; Santini, Francesca; Minuto, Michele; Galleri, David; Miccoli, Paolo.

In: Current Genomics, Vol. 12, No. 8, 12.2011, p. 626-631.

Research output: Contribution to journalArticle

Antonelli, A, Fallahi, P, Ferrari, SM, Ruffilli, I, Santini, F, Minuto, M, Galleri, D & Miccoli, P 2011, 'New targeted therapies for thyroid cancer', Current Genomics, vol. 12, no. 8, pp. 626-631. https://doi.org/10.2174/138920211798120808
Antonelli A, Fallahi P, Ferrari SM, Ruffilli I, Santini F, Minuto M et al. New targeted therapies for thyroid cancer. Current Genomics. 2011 Dec;12(8):626-631. https://doi.org/10.2174/138920211798120808
Antonelli, Alessandro ; Fallahi, Poupak ; Ferrari, Silvia M. ; Ruffilli, Ilaria ; Santini, Francesca ; Minuto, Michele ; Galleri, David ; Miccoli, Paolo. / New targeted therapies for thyroid cancer. In: Current Genomics. 2011 ; Vol. 12, No. 8. pp. 626-631.
@article{6664d875a9594d26a0085fe2fbac8683,
title = "New targeted therapies for thyroid cancer",
abstract = "The increasing incidence of thyroid cancer is associated with a higher number of advanced disease characterized by the loss of cancer differentiation and metastatic spread. The knowledge of the molecular pathways involved in the pathogenesis of thyroid cancer has made possible the development of new therapeutic drugs able to blockade the oncogenic kinases (BRAF V600E, RET/PTC) or signaling kinases [vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptors (PDGFR)] involved in cellular growth and proliferation. Some clinical trials have been conducted showing the ability of targeted therapies (sorafenib, sunitinib, axitinib, imanitib, vandetanib, pazopanib, gefitinib) in stabilizing the course of the disease. Until now, however, no consensus guidelines have been established for patient selection and more data on toxicities and side effects are needed to be collected.",
keywords = "Anaplastic thyroid cancer, Aurora kinase inhibitors, BRAF, Peroxisome proliferator-activated receptor-γ, RET, Targeted molecular therapies, Tyrosine kinase inhibitors, VEGFR",
author = "Alessandro Antonelli and Poupak Fallahi and Ferrari, {Silvia M.} and Ilaria Ruffilli and Francesca Santini and Michele Minuto and David Galleri and Paolo Miccoli",
year = "2011",
month = "12",
doi = "10.2174/138920211798120808",
language = "English",
volume = "12",
pages = "626--631",
journal = "Current Genomics",
issn = "1389-2029",
publisher = "Bentham Science Publishers B.V.",
number = "8",

}

TY - JOUR

T1 - New targeted therapies for thyroid cancer

AU - Antonelli, Alessandro

AU - Fallahi, Poupak

AU - Ferrari, Silvia M.

AU - Ruffilli, Ilaria

AU - Santini, Francesca

AU - Minuto, Michele

AU - Galleri, David

AU - Miccoli, Paolo

PY - 2011/12

Y1 - 2011/12

N2 - The increasing incidence of thyroid cancer is associated with a higher number of advanced disease characterized by the loss of cancer differentiation and metastatic spread. The knowledge of the molecular pathways involved in the pathogenesis of thyroid cancer has made possible the development of new therapeutic drugs able to blockade the oncogenic kinases (BRAF V600E, RET/PTC) or signaling kinases [vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptors (PDGFR)] involved in cellular growth and proliferation. Some clinical trials have been conducted showing the ability of targeted therapies (sorafenib, sunitinib, axitinib, imanitib, vandetanib, pazopanib, gefitinib) in stabilizing the course of the disease. Until now, however, no consensus guidelines have been established for patient selection and more data on toxicities and side effects are needed to be collected.

AB - The increasing incidence of thyroid cancer is associated with a higher number of advanced disease characterized by the loss of cancer differentiation and metastatic spread. The knowledge of the molecular pathways involved in the pathogenesis of thyroid cancer has made possible the development of new therapeutic drugs able to blockade the oncogenic kinases (BRAF V600E, RET/PTC) or signaling kinases [vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptors (PDGFR)] involved in cellular growth and proliferation. Some clinical trials have been conducted showing the ability of targeted therapies (sorafenib, sunitinib, axitinib, imanitib, vandetanib, pazopanib, gefitinib) in stabilizing the course of the disease. Until now, however, no consensus guidelines have been established for patient selection and more data on toxicities and side effects are needed to be collected.

KW - Anaplastic thyroid cancer

KW - Aurora kinase inhibitors

KW - BRAF

KW - Peroxisome proliferator-activated receptor-γ

KW - RET

KW - Targeted molecular therapies

KW - Tyrosine kinase inhibitors

KW - VEGFR

UR - http://www.scopus.com/inward/record.url?scp=82055208201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82055208201&partnerID=8YFLogxK

U2 - 10.2174/138920211798120808

DO - 10.2174/138920211798120808

M3 - Article

C2 - 22654562

AN - SCOPUS:82055208201

VL - 12

SP - 626

EP - 631

JO - Current Genomics

JF - Current Genomics

SN - 1389-2029

IS - 8

ER -